1. Academic Validation
  2. Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis

Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis

  • Antimicrob Agents Chemother. 1991 Feb;35(2):234-6. doi: 10.1128/AAC.35.2.234.
F Isono 1 M Inukai
Affiliations

Affiliation

  • 1 Fermentation Research Laboratories, Sankyo Co. Ltd., Tokyo, Japan.
Abstract

Mureidomycin A (MRD), a novel peptidylnucleoside Antibiotic with antipseudomonal activity, inhibited not only peptidoglycan synthesis but also lipid-intermediate formation from UDP-N-acetylmuramyl (MurNAc)-pentapeptide and UDP-N-acetylglucosamine in an in vitro peptidoglycan-synthesizing system, using ether-treated cells of Pseudomonas aeruginosa. Both types of inhibition by MRD disappeared when UDP-MurNAc-pentapeptide was preincubated with ether-treated cells. Moreover, MRD completely inhibited lipid-intermediate I (undecaprenyl-p-p-MurNAc-pentapeptide) formation at a concentration below the MIC. From these results, it was concluded that the real target of MRD's action was translocase, which catalyzes lipid-intermediate I formation from UDP-MurNAc-pentapeptide and a lipid carrier.

Figures
Products